344 related articles for article (PubMed ID: 32086342)
21. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
[TBL] [Abstract][Full Text] [Related]
22. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.
Yang K; Guo W; Ren T; Huang Y; Han Y; Zhang H; Zhang J
J Exp Clin Cancer Res; 2019 May; 38(1):185. PubMed ID: 31053152
[TBL] [Abstract][Full Text] [Related]
24. Pan-cancer molecular analysis of the RB tumor suppressor pathway.
Knudsen ES; Nambiar R; Rosario SR; Smiraglia DJ; Goodrich DW; Witkiewicz AK
Commun Biol; 2020 Apr; 3(1):158. PubMed ID: 32242058
[TBL] [Abstract][Full Text] [Related]
25. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
[TBL] [Abstract][Full Text] [Related]
26. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
27. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.
Knudsen ES; Pruitt SC; Hershberger PA; Witkiewicz AK; Goodrich DW
Trends Cancer; 2019 May; 5(5):308-324. PubMed ID: 31174843
[TBL] [Abstract][Full Text] [Related]
28. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER
Palafox M; Monserrat L; Bellet M; Villacampa G; Gonzalez-Perez A; Oliveira M; Brasó-Maristany F; Ibrahimi N; Kannan S; Mina L; Herrera-Abreu MT; Òdena A; Sánchez-Guixé M; Capelán M; Azaro A; Bruna A; Rodríguez O; Guzmán M; Grueso J; Viaplana C; Hernández J; Su F; Lin K; Clarke RB; Caldas C; Arribas J; Michiels S; García-Sanz A; Turner NC; Prat A; Nuciforo P; Dienstmann R; Verma CS; Lopez-Bigas N; Scaltriti M; Arnedos M; Saura C; Serra V
Nat Commun; 2022 Sep; 13(1):5258. PubMed ID: 36071033
[TBL] [Abstract][Full Text] [Related]
29. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
30. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
31. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
Condorelli R; Spring L; O'Shaughnessy J; Lacroix L; Bailleux C; Scott V; Dubois J; Nagy RJ; Lanman RB; Iafrate AJ; Andre F; Bardia A
Ann Oncol; 2018 Mar; 29(3):640-645. PubMed ID: 29236940
[TBL] [Abstract][Full Text] [Related]
32. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
[TBL] [Abstract][Full Text] [Related]
33. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
Grit JL; McGee LE; Tovar EA; Essenburg CJ; Wolfrum E; Beddows I; Williams K; Sheridan RTC; Schipper JL; Adams M; Arumugam M; Vander Woude T; Gurunathan S; Field JM; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Oncogene; 2024 May; 43(19):1411-1430. PubMed ID: 38480916
[TBL] [Abstract][Full Text] [Related]
34. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
Zhou Y; Jin X; Ma J; Ding D; Huang Z; Sheng H; Yan Y; Pan Y; Wei T; Wang L; Wu H; Huang H
Cancer Res; 2021 Mar; 81(6):1486-1499. PubMed ID: 33419772
[TBL] [Abstract][Full Text] [Related]
35. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
[TBL] [Abstract][Full Text] [Related]
36. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
[TBL] [Abstract][Full Text] [Related]
37. Targeting the RB-E2F pathway in breast cancer.
Johnson J; Thijssen B; McDermott U; Garnett M; Wessels LF; Bernards R
Oncogene; 2016 Sep; 35(37):4829-35. PubMed ID: 26923330
[TBL] [Abstract][Full Text] [Related]
38. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
[TBL] [Abstract][Full Text] [Related]
39. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
[TBL] [Abstract][Full Text] [Related]
40. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer.
Rampioni Vinciguerra GL; Dall'Acqua A; Segatto I; Mattevi MC; Russo F; Favero A; Cirombella R; Mungo G; Viotto D; Karimbayli J; Pesce M; Vecchione A; Belletti B; Baldassarre G
Cell Death Dis; 2021 Oct; 12(10):951. PubMed ID: 34654798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
